Additionally, the 36-month beta value for CARM is 1.06. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CARM is 19.35M and currently, short sellers hold a 8.17% ratio of that float. The average trading volume of CARM on April 23, 2024 was 166.23K shares.
CARM) stock’s latest price update
The stock price of Carisma Therapeutics Inc (NASDAQ: CARM) has jumped by 14.72 compared to previous close of 1.63. Despite this, the company has seen a gain of 6.25% in its stock price over the last five trading days. PRNewsWire reported 2024-04-22 that Preclinical data highlights the potential of engineered macrophage cell therapy as a treatment for liver and lung fibrosis Novel Redirected Soluble Modulator technology has demonstrated the potential to enhance immune receptor signaling PHILADELPHIA, April 22, 2024 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the acceptance of two abstracts at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting being held May 7-11, 2024, in Baltimore, MD. “We are excited to present new preclinical data highlighting the potential of our engineered macrophage cell therapies for the treatment of liver and lung fibrosis, both of which represent significant unmet medical needs with limited available therapies for patients,” said Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer of Carisma.
CARM’s Market Performance
CARM’s stock has risen by 6.25% in the past week, with a monthly drop of -25.50% and a quarterly drop of -23.67%. The volatility ratio for the week is 9.65% while the volatility levels for the last 30 days are 9.20% for Carisma Therapeutics Inc The simple moving average for the past 20 days is -6.22% for CARM’s stock, with a -49.69% simple moving average for the past 200 days.
Analysts’ Opinion of CARM
Many brokerage firms have already submitted their reports for CARM stocks, with BTIG Research repeating the rating for CARM by listing it as a “Buy.” The predicted price for CARM in the upcoming period, according to BTIG Research is $6 based on the research report published on April 11, 2024 of the current year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see CARM reach a price target of $10. The rating they have provided for CARM stocks is “Overweight” according to the report published on October 03rd, 2023.
Evercore ISI gave a rating of “Outperform” to CARM, setting the target price at $12 in the report published on July 06th of the previous year.
CARM Trading at -16.56% from the 50-Day Moving Average
After a stumble in the market that brought CARM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.85% of loss for the given period.
Volatility was left at 9.20%, however, over the last 30 days, the volatility rate increased by 9.65%, as shares sank -23.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.95% lower at present.
During the last 5 trading sessions, CARM rose by +6.25%, which changed the moving average for the period of 200-days by -77.82% in comparison to the 20-day moving average, which settled at $1.9655. In addition, Carisma Therapeutics Inc saw -36.18% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CARM
Current profitability levels for the company are sitting at:
- -5.95 for the present operating margin
- 0.72 for the gross margin
The net margin for Carisma Therapeutics Inc stands at -5.82. The total capital return value is set at -1.2. Equity return is now at value -94.06, with -48.11 for asset returns.
Based on Carisma Therapeutics Inc (CARM), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -26.04. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -53.94.
Currently, EBITDA for the company is -80.47 million with net debt to EBITDA at 0.87. When we switch over and look at the enterprise to sales, we see a ratio of 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.06.
Conclusion
In conclusion, Carisma Therapeutics Inc (CARM) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
